What is Zacks Research’s Estimate for Stryker Q4 Earnings?

Stryker Co. (NYSE:SYK) – Investment analysts at Zacks Research raised their Q4 2025 earnings per share estimates for Stryker in a report released on Tuesday, February 18th. Zacks Research analyst I. Bandyopadhyay now expects that the medical technology company will post earnings of $4.34 per share for the quarter, up from their previous forecast of $4.23. The consensus estimate for Stryker’s current full-year earnings is $13.49 per share. Zacks Research also issued estimates for Stryker’s Q4 2026 earnings at $4.65 EPS and FY2027 earnings at $16.40 EPS.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the firm posted $3.46 EPS.

A number of other analysts also recently commented on the stock. Robert W. Baird boosted their target price on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $420.00 price target (up previously from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Wells Fargo & Company upped their target price on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. lifted their price target on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $420.68.

Stryker Price Performance

Shares of NYSE SYK opened at $388.30 on Thursday. Stryker has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average of $377.69 and a two-hundred day moving average of $368.08. The company has a market capitalization of $148.17 billion, a price-to-earnings ratio of 50.04, a PEG ratio of 2.90 and a beta of 0.96.

Hedge Funds Weigh In On Stryker

A number of institutional investors and hedge funds have recently bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC bought a new position in shares of Stryker during the 4th quarter worth about $25,000. Dunhill Financial LLC increased its stake in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares during the period. Rakuten Securities Inc. raised its holdings in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in Stryker in the 4th quarter valued at approximately $30,000. Finally, BankPlus Trust Department bought a new stake in shares of Stryker in the 4th quarter worth approximately $33,000. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.87%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.